Tags OTCQX
Tag: OTCQX
BioLargo’s AEC PFAS platform continues to prove promising, but underreported risks in operational resilience might complicate further commercialization.
BioLargo expands PFAS, Clyra, and BLEST operations while working to recover from the financial fallout tied to Pooph®.
BioLargo enters early commercialization with Clyra and PFAS, but steep revenue loss from Pooph® collapse leaves execution and scaling critical in 2026.
BioLargo's Q3 2025 report shows tech traction in PFAS, Clyra™, and Cellinity™ — but monetization remains elusive post-Pooph® fallout.
BioLargo's Q2 exposes value-chain gaps—regulatory lags, partner dependency, and no clear path from validation to revenue.
BioLargo’s growth hinges on its AEC, Clyra™, and Pooph® innovations, but delays and cash burn turn Q2–Q3 into a critical test for its long-term ambitions.
BioLargo's recent financials and corporate updates highlight continued growth of its AEC PFAS-removal technology soon to be operational at commercial scale.
BioLargo's recent financials and corporate updates highlight more strengths and opportunities over weaknesses and threats among its products and services, including PFAS removal.
Just to mention a few of the latest buzzworthy OTC movers that may “ring a bell.”
More than 12,000 stocks trade Over the Counter
